Literature DB >> 8963725

Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation.

J Torzewski1, R Oldroyd, P Lachmann, C Fitzsimmons, D Proudfoot, D Bowyer.   

Abstract

Increasing evidence suggests that complement activation might represent an important mechanism in early atherogenesis. Thus, complement components, in particular the membrane attack complex (MAC) C5b-9(m), have been isolated from human atherosclerotic lesions. Furthermore, complement activation is known to occur in atherosclerotic lesions induced in experimental animals, and the severity of cholesterol-induced plaques is markedly reduced in complement-deficient animals. During atherogenesis monocytes are recruited into the arterial wall, and a potent chemoattractant for monocytes, monocyte chemotactic protein-1 (MCP-1), is expressed by vascular smooth muscle cells (SMCs). We hypothesized that generation of MACs on SMCs during the activation of complement might lead to the release of MCP-1 and hence to monocyte recruitment. In this study, MACs were generated on human SMCs in vitro by sequential addition of the purified complement components C5b6, C7, C8, and C9. This supernatant of the culture was chemotactic for freshly isolated peripheral blood monocytes in a modified Boyden chamber. The chemotactic activity of the supernatant was abolished by anti-MCP-1 blocking antibodies but not by an isotype-matched antibody against an irrelevant antigen. The release of chemotactic activity was dependent on the dose of MAC formed on SMCs and was demonstrated within 10 minutes of exposure of the cells. The data support the hypothesis that complement-mediated release of MCP-1 from SMCs might be important in the recruitment of monocytes into the developing atherosclerotic lesion and could be an important initiating event in atherogenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8963725     DOI: 10.1161/01.atv.16.5.673

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  23 in total

1.  Relationship between complement membrane attack complex, chemokine (C-C motif) ligand 2 (CCL2) and vascular endothelial growth factor in mouse model of laser-induced choroidal neovascularization.

Authors:  Juan Liu; Purushottam Jha; Valeriy V Lyzogubov; Ruslana G Tytarenko; Nalini S Bora; Puran S Bora
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

Review 2.  Role of chemokines, innate and adaptive immunity.

Authors:  Kurt A Zimmerman; Katharina Hopp; Michal Mrug
Journal:  Cell Signal       Date:  2020-04-20       Impact factor: 4.315

Review 3.  Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.

Authors:  Maureen McMahon; Bevra H Hahn; Brian J Skaggs
Journal:  Expert Rev Clin Immunol       Date:  2011-03       Impact factor: 4.473

Review 4.  Accelerated vascular disease in systemic lupus erythematosus: role of macrophage.

Authors:  Mohammed M Al Gadban; Mohamed M Alwan; Kent J Smith; Samar M Hammad
Journal:  Clin Immunol       Date:  2015-01-28       Impact factor: 3.969

5.  Molecular basis for a link between complement and the vascular complications of diabetes.

Authors:  J Acosta; J Hettinga; R Flückiger; N Krumrei; A Goldfine; L Angarita; J Halperin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

6.  Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation.

Authors:  K S Kilgore; E Schmid; T P Shanley; C M Flory; V Maheswari; N L Tramontini; H Cohen; P A Ward; H P Friedl; J S Warren
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

Review 7.  Role of complement and complement regulatory proteins in the complications of diabetes.

Authors:  Pamela Ghosh; Rupam Sahoo; Anand Vaidya; Michael Chorev; Jose A Halperin
Journal:  Endocr Rev       Date:  2015-04-10       Impact factor: 19.871

8.  Complement and dilated cardiomyopathy: a role of sublytic terminal complement complex-induced tumor necrosis factor-alpha synthesis in cardiac myocytes.

Authors:  Thomas P Zwaka; Dimitar Manolov; Cüneyt Ozdemir; Nikolaus Marx; Ziya Kaya; Matthias Kochs; Martin Höher; Vinzenz Hombach; Jan Torzewski
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

Review 9.  The role of complement activation in atherosclerosis.

Authors:  Florin Niculescu; Horea Rus
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

10.  Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex.

Authors:  Gongxiong Wu; Weiguo Hu; Aliakbar Shahsafaei; Wenping Song; Martin Dobarro; Galina K Sukhova; Rod R Bronson; Guo-Ping Shi; Russell P Rother; Jose A Halperin; Xuebin Qin
Journal:  Circ Res       Date:  2009-01-08       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.